BTK Inhibitor
Catherine Coombs, MD, discusses Bruton’s tyrosine kinase inhibitors at the 2022 SOHO Annual Meeting.
As treatments for CLL evolve, new challenges have arisen to address the disease’s resistance to targeted therapies.
Because WM is considered incurable, an important treatment consideration is optimization of quality of life.
Advertisement
Zanubrutinib led to significant PFS improvements compared with bendamustine plus rituximab in patients with CLL or SLL.
The FDA has approved the new tablet formulation of acalabrutinib for CLL, SLL, and R/R MCL.
The European Commission has granted Marketing Authorization for the expanded use of ibrutinib.
Advertisement
Frontline Ibrutinib Plus Standard Chemoimmunotherapy Shows Benefit in Untreated Mantle Cell Lymphoma
Ibrutinib combined with standard chemoimmunotherapy significantly prolonged progression-free survival in older patients.This article discusses managing the most difficult cases of CLL.
The phase I/II study examined the use of the Bruton’s tyrosine kinase inhibitor in 385 patients.
Three-year follow-up data from the CAPTIVATE trial were presented at the 2022 ASCO Annual Meeting.
The study included adults with treatment-naïve and relapsed/refractory CLL or small lymphocytic leukemia.
Updated findings from the ASCEND study were presented at the 2022 ASCO Annual Meeting.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.